Prophylactic use of low-dose PPI and recurrence of upper gastro-intetinal peptic ulcer in long-term Users of Nonsteroidal Anti-inflammatory Drugs(NSAIDs) or low-dose aspirin(LDA)

Prophylactic use of low-dose PPI and recurrence of upper gastro-intetinal peptic ulcer in long-term Users of Nonsteroidal Anti-inflammatory Drugs(NSAIDs) or low-dose aspirin(LDA) - Prophylactic use of low-dose PPI and recurrence of upper gastro-intetinal peptic ulcer in long-term Users of Nonsteroidal Anti-inflammatory Drugs(NSAIDs) or low-dose aspirin(LDA)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005766

Enrollment

Registered

2011-06-15

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic Ulcer

Interventions

changing to lansoprazole 15 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients taking NSAIDs or LDA for more than a month 2)Patioents taking standard-dose PPI(omeprazole20mg,lansoprazole30mg, rabeprazole10mg) 3)Patients with past history of endoscopically documented gastric or duodenal ulcer 4)Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with allergy for lansoprazole 2)Patients with allergy of atazanavir sulfate 3) Patients under treatment of peptic ulcer 4)Over Grade A reflux esophagitis according to Los Angeles classification (LA classification)

Design outcomes

Primary

Measure	Time frame
Incidence rate of gastric or duodenal ulcer after treatment (gastrointestinal mucosal disorder with a lesion greater than or equal to 5 mm in diameter)	—

Secondary

Measure	Time frame
Changes in digestive symptom(GSRS) and gastro-intestinal mucosal injury (Mofified Lanza-Score), Incidence rate of Gastroesophageal reflux disease	—

Countries

Japan

Contacts

Public ContactTetsuya Tanigawa

Osaka City University Graduate School of Medicine Department of Gastroenterology

ttanigawa@med.osaka-cu.ac.jp06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026